Professional Documents
Culture Documents
Europe | 4Q | 2015
The following report presents Dow Jones VentureSources quarterly findings for European venture capital fundraising, investment, valuation,
and liquidity. The included charts and graphs offer a comprehensive view of the trends currently affecting the venture capital market.
Highlights for 4Q 2015 include:
European venture capital fundraising and fund closings climbed from prior quarter;
Venture capital investment into European companies declined from 3Q 2015, while the number of deals improved;
The number of mergers and acquisitions (M&As) experienced a decrease from the last quarter, while the number of initial public offerings (IPOs)
is on the rise.
European VC Fundraising
Based on multiple closings (20122015)
45
2.50
40
2.00
35
30
1.50
25
20
1.00
15
10
0.50
5
0
Amount Raised (B)
Number of Funds
4Q'12
1Q'13
2Q'13
3Q'13
4Q'13
1Q'14
2Q'14
3Q'14
4Q'14
1Q'15
1.42 0.76 1.03 0.65 1.94 0.55 1.26 0.81 1.26 1.06
32
15
17
12
41
22
24
20
27
22
2Q'15
3Q'15
0.00
4Q'15
12
19
Firm Name
Fund Name
Amount (M)
Location
Offering
Status
Fund Type
Fund Category
Closing Type
Sofinnova Partners
300.00
Paris,
France
Closed
Early-stage venture
capital
Venture Capital
Final
170.00
Munich,
Germany
Closed
Late-stage venture
capital
Venture Capital
Final
Partech Ventures
Partech Growth
170.00
Paris,
France
Open
Late-stage venture
capital
Venture Capital
121.62
London,
United Kingdom
Closed
Late-stage venture
capital
Venture Capital
100
Espoo,
Finland
Closed
Early-stage venture
capital
Venture Capital
First
Final
Final
European companies raised over 3.3 billion for 426 deals during
4Q 2015, a 1% decline in the amount raised from the prior quarter
despite a 14% rise in the number of deals.
500
450
3.50
400
3.00
350
2.50
300
2.00
250
200
1.50
150
1.00
100
0.50
0.00
50
4Q'12
1Q'13
1Q'14
1Q'15
Amount Raised (B) 1.28 1.24 1.54 1.80 1.98 1.64 2.43 2.32 2.05 2.83 3.52 3.32 3.29
Number of Deals
405
391
434
410
499
412
450
361
411
405
393
374
426
4Q'12
1Q'13
2Q'13
3Q'13
4Q'13
1Q'14
2Q'14
3Q'14
4Q'14
1Q'15
2Q'15
3Q'15
Seed
66
41
40
57
75
39
32
26
35
21
26
26
4Q'15
29
First
200
205
215
213
223
219
227
182
200
204
179
178
229
Second
61
66
87
65
85
64
92
66
76
79
73
78
82
Later
45
54
65
51
82
60
78
62
60
79
96
75
62
Restart
2,000
1,500
1,000
500
4Q'12
1Q'13
2Q'13
3Q'13
4Q'13
1Q'14
2Q'14
3Q'14
4Q'14
1Q'15
2Q'15
3Q'15
Seed
27
21
17
23
31
18
22
15
27
16
17
29
20
First
464
401
429
543
491
513
625
461
453
606
509
808
725
Second
299
258
472
706
402
306
477
220
775
451
922
571
578
Later
458
540
600
461
995
679
1,124
900
751
1,691
1,937
1,861
1,511
Restart
4Q'15
2.50
2.00
1.50
1.00
0.50
0.00
Median Equity Deal Size (M)
4Q'12
1Q'13
2Q'13
3Q'13
4Q'13
1Q'14
2Q'14
3Q'14
4Q'14
1Q'15
2Q'15
3Q'15
4Q'15
1.20
1.39
1.52
1.00
1.25
1.50
1.74
1.58
2.00
1.98
2.50
2.30
2.22
4Q'15 Industry
Breakdown
By Number
of Deals
Consumer Goods
Consumer Services
3%
1%
23%
17%
26%
2%
4Q15 Industry
Breakdown
By Amount
Raised
26%
Consumer Goods
1%
3%
Consumer Services
Energy & Utilities
Healthcare
24%
23%
1%
Co. Name
Location
O3B Networks
Ltd.
St. Helier,
United
Kingdom
Industry
Code
Wireless
Telecommunic Communications and
ations Service
Networking
Providers
Skyscanner Ltd.
Edinburgh,
United
Kingdom
Search Portals
auxmoney
GmbH
Gdusseldorf,
Germany
Lending
CureVac AG
Industry
Segment
Consumer
Information Services
Brief
Description
Close
Date
Round
Type
Raised
(M)
Round Investors
(* denotes lead)
Information
Technology
10/12/2015
5th
Round
427.83
Later
Round
179.94
Corporate
150
Aegon*
Later
Round
100
Corporate
93.78
Vertex Pharmaceuticals*
Consumer Services
Tuebingen, Biotechnology
Biopharmaceuticals
Germany
Therapeutics
Crispr
Basel,
Therapeutics AG Switzerland
Industry
Group
Biotechnology
Therapeutics Biopharmaceuticals
Healthcare
Healthcare
Developer of genome-editing
technologies for the treatment of 26/10/2015
serious human genetic diseases.
29/10/2015
10
16
14
12
11
10
8
8
7
6
Seedcamp
Mercia Technologies
PLC
Index Ventures
6
4
2
0
High-Tech
Bpifrance Investment
Gruenderfonds
Management GmbH
Partech Ventures
Idinvest Partners
11
The United Kingdom remained as the most favoured destination for equity
financing during 4Q 2015, receiving 1403 million across 111 deals. The country
took 43% of all equity financing from 4Q 2015.
Germany ranked second. It reached a total 685 million through 78 deals,
representing a 21% share of European financing. A 92% rise in capital invested
and 11% increase of the number of deals from last quarter.
France occupied third position raising 379 million, 12% of the total for the
quarter. Switzerland placed fourth ,raising 316 million during 4Q 2015.
United Kingdom
26%
29%
France
Germany
6%
23%
21%
Spain
18%
Rest of Europe
Amount Raised
in 4Q 2015
by Country
(Top 4)
United Kingdom
15%
Germany
10%
43%
France
19%
11%
Switzerland
21%
Rest of Europe
12
4Q'15
3Q'15
2Q'15
1Q'15
4Q'14
3Q'14
2Q'14
1Q'14
4Q'13
3Q'13
2Q'13
1Q'13
4Q'12
0
4Q'12
10
1Q'13
2Q'13
20
3Q'13
4Q'13
30
1Q'14
2Q'14
40
3Q'14
4Q'14
50
1Q'15
2Q'15
60
3Q'15
70
4Q'15
IPOs
21
16
10
12
15
13
M&As
47
37
40
42
44
56
42
50
49
53
43
49
38
13
Company Name
Location
Brief
Description
Industry
Code
Industry Segment
Industry Group
Close
Date
Round
Type
Amount Paid
(M)
Acquirer
Acerta Pharma
B.V.
Oss,
Netherlands
Biotechnology
Therapeutics
Biopharmaceuticals
Healthcare
17/12/2015
Acquisition
2296.03
AstraZeneca Plc
Dezima Pharma
B.V.
Naarden,
Netherlands
Pharmaceuticals
Biopharmaceuticals
Healthcare
16/10/2015
Acquisition
1339.76
Amgen Inc.
Avito.ru
Moscow,
Russia
Provider of a classified
advertising website.
Shopping
Facilitators
23/10/2015
Acquisition
1071.81
Naspers
Consumer
Consumer Services
Information Services
14
2,500.00
25
2,000.00
20
1,500.00
15
1,000.00
10
500.00
0.00
4Q'12
1Q'13
2Q'13
89.24
5
3Q'13
4Q'13
1Q'14
2Q'14
3Q'14
4Q'14
1Q'15
2Q'15
3Q'15
4Q'15
25.51 366.10 448.63 529.53 447.47 2,250 417.40 533.10 699.69 511.42
3
21
16
10
12
15
13
15
Company Name
Location
Brief
Description
Industry
Code
Industry Segment
Industry Group
Close
Date
Raised through
IPO (M)
Exchange/
Symbol
NovoCure Ltd.
United Kingdom
Biotechnology
Therapeutics
Biopharmaceuticals
Healthcare
2/10/2015
147.37
Nasdaq: NVCR
Mimecast Ltd.
United Kingdom
Software
Information
Technology
19/11/2015
70.42
NASDAQ: MIME
Advanced
Accelerator
Applications SA
France
Biopharmaceuticals
Healthcare
11/11/2015
68.15
NASDAQ: AAAP
Network/Systems
Provider of cloud security solutions. Management Software
Biotechnology
Therapeutics
16
ABOUT US
Dow Jones VentureSource helps venture capitalists, corporate development executives, investment bankers and service provider find deal and
partnership opportunities, perform comprehensive due diligence and examine trends in venture capital investment, fund-raising and liquidity. It provides
accurate, comprehensive data on venture-backed companies including their investors and executives in every region, industry and stage of
development throughout the world.
The investment figures included in this release are based on aggregate findings of Dow Jones proprietary research and are contained in VentureSource.
This data was collected through survey of professional firms, interviews with company executives, and from secondary sources. These venture capital
statistics cover equity investments into early stage, innovative companies and do not include companies receiving funding solely from corporate,
individual, and/or government investors. Figures contained throughout the report current at time of editorial but are subject to change without notice.
No statement herein is to be construed as a recommendation to buy or sell securities or to provide investment advice.
17
Dow Jones is a global provider of news and business information, delivering content to consumers and organizations around the world across multiple
formats, including print digital, mobile and live events. Dow Jones has produced unrivaled quality content for more than 125 years and today has one of
the worlds largest newsgathering operations globally. It produces leading publications and products including the flagship Wall Street Journal,
Americas largest newspaper by paid circulation; Factiva, Barrons, MarketWatch, Financial News, DJX, Dow Jones Risk & Compliance, Dow Jones
Newswires, and Dow Jones VentureSource.
MEDIA CONTACT:
Hannah Syrocki
hannah.syrocki@dowjones.com
44 (0)20 7573 4059
18